Latest Information Update: 17 Aug 2001
At a glance
- Originator Novartis
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 Aug 2001 No-Development-Reported for Cancer in Switzerland (Unknown route)
- 15 Jan 1996 Phase-I clinical trials for Cancer in Switzerland (Unknown route)